Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of BL-M07D1 Combination Therapy in Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
CTR20242193Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1 in HER2-positive gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Biokin Pharmaceutical. Started Jan 2025; status: active.
02
Drugs
BL-M07D1
03
Conditions
HER2-positive gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20242193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242193.